medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2014, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2014; 61 (3)

Stem-cell mobilization with recombinant human granulocyte colony stimulating factor in patients with postoperative myocardial infarction after coronary artery bypass graft

Aidroos AH, Valdés RY, Carnot UJ, Diego CJ, Marcel EA, Colao-Jiménez Y, Chaos-González N, Amador-Acuña MG, Romero-González R

Language: Spanish
References: 27
Page: 150-155
PDF size: 149.99 Kb.


ABSTRACT

Cuasi experimental Clinical trials about the stem-cells movilization by LeukoCim or filgastrin (Cuban recombinant human granulocyte colony stimulating factor (G-CSF), in 10 patients with an average age of 55.3 ± 7.5 years who had coronary artery bypass graft and later presented postoperation myocardial infarction .The realized stem-cell movilization using (G-CSF) granulocyte colony stimulating factor in patients who had a coronary artery bypass graft with postmyocardial infarction (IMAP) at a doseye of 10 µg/kg/day of body weight divided in two subdosages daily, by means of subcutaneous for five days and repeated the same routine a month later. Blood cell counts and inmunophenotyping were done to asses the total number of circulating CD34+ cells. At 3 months follow up functional recovery was evaluated and defined as an increase in ejection fraction. The evolution of patients during the study was without major complications. The gain in ejection fraction was of 11% ± 7.7 and correlated directly with the total number of circulating CD34+ cells (2.18% ± 1.05). Stem-cell mobilization with G-CSF is a feasible and safe treatment for patients with postoperative myocardial infarction after coronary surgery. The possibility of leucocytosis or trombocytosis during G-CSF administration should be taken into account.


REFERENCES

  1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS et al. Embryonic stem-cell lines derived from human blastocysts. Science. 1998; 282: 1145-1147.

  2. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999; 100: 247-256.

  3. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001; 410: 701-705.

  4. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem-cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105: 93-98.

  5. Orlic D, Hill JM, Arai AE. Stem-cells for myocardial regeneration. Circ Res. 2002; 91: 1092-1102.

  6. Strauer BE, Brehm M, Zeus T, Kostering M, Hernández A, Sorg RV et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cells transplantation in humans. Circulation. 2002; 106: 1913-1918.

  7. Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Dobert N et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002; 106: 3009-3017.

  8. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003; 361: 45-46.

  9. Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. A feasibility study. J Am Coll Cardiol. 2003; 41: 1721-1724.

  10. Menasche P, Hagege A, Vilquin JT, Desnos M, Abergel E, Pouzet B et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003; 41: 1078-1083.

  11. Avilés FF, San Román JA, García J, Valdés M, Sánchez A, De la Fuente L et al. Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio. Rev Esp Cardiol. 2004; 57: 201-208.

  12. Welte K, Bonilla MA, Gillio AP et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987; 165: 941-948.

  13. Suárez de Lezo J et al. Movilización de células madre en el infarto agudo de miocardio. Rev Esp Cardiol. 2005; 58 (3): 253-261.

  14. Strauer BE, Brehm M, Zeus T, Kostering M, Hernández A, Sorg RV et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cells transplantation in humans. Circulation. 2002; 106: 1913-1918.

  15. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003; 361: 45-46.

  16. Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. A feasibility study. J Am Coll Cardiol. 2003; 41: 1721-1724.

  17. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F et al. Mobilized bone marrow cells repair the infarcted heart improving function and survival. Proc Natl Acad Sci USA. 2001; 98: 10344-10349.

  18. Norol F, Merlet P, Isnard R, Sebillon P, Bonnet N, Cailliot C et al. Influence of mobilized stem-cells on myocardial infarct repair in a nonhuman primate mode. Blood. 2003; 102: 4361-4368.

  19. Hernández-Núñez R. Revascularización miocárdica. Estudio comparativo de diferentes técnicas [trabajo de terminación de residencia]. La Habana, Cuba: Servicio de Cirugía cardiovascular, Hospital Hermanos Ameijeiras; 2005.

  20. Nathanael-Hidalgo R. Revascularización miocárdica. Estudio comparativo de diferentes técnicas [trabajo de terminación de residencia]. La Habana, Cuba: Servicio de Cirugía cardiovascular, Hospital Hermanos Ameijeiras; 2012.

  21. Khan NE, De Souza A, Mister R, Flather M, Clague J, Davies S et al. A randomized comparison of off-pump and on- pump multivessel coronary-artery bypass surgery. N Engl J Med. 2008; 350: 21-28.

  22. Takagi H. Off-pump surgery does not reduce stroke, compared with results of on pump coronary artery bypass grafting: a meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2007; 134: 1059-1060.

  23. Shroyer AL. On-pump versus off-pump coronary-artery bypass surgery (ROOBY). New Engl J Med. 2009; 361: 1827-1837.

  24. Radcliffe J. Does off-pump total arterial grafting increase the incidence of intraoperative graft failure? Circulation. 2007; 116: 1108-1109.

  25. Kirklin JK, Westaby S, Blackstone EH et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1983; 86: 845-857.

  26. Socarrás-Ferrer BB, Macías AC, Del Valle-Pérez L, Marsán-Suárez V, Vergara-Castellanos J, Lam-Díaz RM et al. Comparación de la actividad de 2 factores estimuladores de colonias de granulocitos de producción nacional: Hebervital y Leukocim. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2011 Dic [acceso 01 de septiembre de 2012]; 27 (4): 429-434. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892011000400007&lng=es

  27. González-Iglesias A, Forrellat-Barrios M, González-Suárez T, Salgado-Arozena O, Fernández-Delgado ND, Hernández-Ramírez P et al. Obtención y procesamiento de progenitores hematopoyéticos de sangre periférica para terapia celular en enfermedades angiológicas. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2011 Sep [acceso 01 de septiembre de 2012]; 27 (3): 356-364. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892011000300012&lng=es




2020     |     www.medigraphic.com